Search | IOVS | ARVO Journals

Showing 1 – 20 of 25

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract July 2019

A Phase 2 Multicenter, Randomized, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of CBT-001 for Pterygia

Scott M Whitcup; Kenneth N Sall; John A. Hovanesian; Damien F. Goldberg; Paula Bernstein; Olivia L Lee

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6246. doi:

Review January 2018

Pharmacology of Corticosteroids for Diabetic Macular Edema

PDF

Scott M. Whitcup; John A. Cidlowski; Karl G. Csaky; Jayakrishna Ambati
TAGS: adrenal corticosteroids, glucocorticoids, mineralocorticoids, macular edema, diabetic
Invest. Ophthalmol. Vis. Sci.. 2018; 59(1):1-12. doi: https://doi.org/10.1167/iovs.17-22259

ARVO Annual Meeting Abstract June 2017

Persistent diabetic macular edema after 6 months of anti-VEGF therapy is associated with diminished long-term improvement in vision: a post-hoc analysis of Protocol I

Scott M Whitcup; Joanna Campbell; Anat Loewenstein; Pravin U Dugel; Nancy Holekamp; Szilard Kiss; Albert J Augustin; Vanessa Shih; Jeff Lai; Charles Clifton Wykoff; Srinivas R Sadda

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1906. doi:

ARVO Annual Meeting Abstract September 2016

Consistency of visual acuity response to anti-VEGF therapy in diabetic macular edema patients: An analysis of DRCRnet Protocol I data

Scott M Whitcup; Joanna Campbell; Nancy Holekamp; Szilard Kiss; Anat Loewenstein; Albert J Augustin; Allen C Ho; Victor Gonzalez; Vanessa Shih; Amelia Orejudos; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract April 2014

Long-term Efficacy and Safety of Dexamethasone Intravitreal Implant in Phakic and Pseudophakic Eyes with Diabetic Macular Edema

Young Hee Yoon; David S Boyer; Rubens Belfort, Jr.; Francesco Bandello; Raj K Maturi; Albert J Augustin; Xiao-Yan Li; Harry Cui; Yehia Hashad; Scott M Whitcup; Ozurdex MEAD Study Group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1779. doi:

ARVO Annual Meeting Abstract April 2014

Anatomic Outcomes with Dexamethasone Intravitreal Implant in Diabetic Macular Edema: a Pooled Analysis of Two Randomized Phase 3 Trials

Ronald P Danis; Srinivas R Sadda; Harry Cui; Xiao-Yan Li; Yehia Hashad; Scott M Whitcup; Ozurdex MEAD Study Group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):5051. doi:

ARVO Annual Meeting Abstract April 2014

Three-year, Randomized, Sham-controlled, Phase III Study of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema

Rubens Belfort, Jr.; David S Boyer; Young Hee Yoon; Francesco Bandello; Raj K Maturi; Albert J Augustin; Xiao-Yan Li; Harry Cui; Yehia Hashad; Scott M Whitcup; Ozurdex MEAD Study Group

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1706. doi:

Clinical Trials July 2013

Vision-Related Functioning Outcomes of Dexamethasone Intravitreal Implant in Noninfectious Intermediate or Posterior Uveitis

PDF

Susan Lightman; Rubens Belfort, Jr.; Rupali K. Naik; Careen Lowder; C. Stephen Foster; Anne M. Rentz; Harry Cui; Scott M. Whitcup; Jonathan W. Kowalski; Dennis A. Revicki
TAGS: dexamethasone, implants, uveitis, posterior, vision, intravitreal implants
Invest. Ophthalmol. Vis. Sci.. 2013; 54(7):4864-4870. doi: https://doi.org/10.1167/iovs.12-10981

Includes: Supplemental Content

Retina June 2011

Pharmacokinetics of a Sustained-Release Dexamethasone Intravitreal Implant in Vitrectomized and Nonvitrectomized Eyes

PDF

Joan-En Chang-Lin; James A. Burke; Qing Peng; Ton Lin; Werhner C. Orilla; Corine R. Ghosn; Kai-Ming Zhang; Baruch D. Kuppermann; Michael R. Robinson; Scott M. Whitcup; Devin F. Welty
TAGS: dexamethasone, eye, implants, intravitreal implants, pharmacokinetics, vitrectomy, vitreous body, retina
Invest. Ophthalmol. Vis. Sci.. 2011; 52(7):4605-4609. doi: https://doi.org/10.1167/iovs.10-6387

Physiology and Pharmacology May 2011

Treatment of Experimental Anterior and Intermediate Uveitis by a Dexamethasone Intravitreal Implant

PDF

Corine R. Ghosn; Yong Li; Werhner C. Orilla; Ton Lin; Larry Wheeler; James A. Burke; Michael R. Robinson; Scott M. Whitcup
TAGS: dexamethasone, eye, histopathology tests, implants, inflammation, inflammatory markers, intravitreal implants, uveitis, uveitis, intermediate, immune reconstitution inflammatory syndrome
Invest. Ophthalmol. Vis. Sci.. 2011; 52(6):2917-2923. doi: https://doi.org/10.1167/iovs.10-5939

Includes: Supplemental Content

ARVO Annual Meeting Abstract April 2011

Association Between Duration of Macular Edema and Clinical Outcomes in Patients with Retinal Vein Occlusion Following Treatment With Dexamethasone Intravitreal Implant

Wei-Shi D. Yeh; Julia A. Haller; Baruch D. Kuppermann; Paul Mitchell; Paolo Lanzetta; Scott M. Whitcup; Tien Y. Wong; Jonathan W. Kowalski

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3965. doi:

ARVO Annual Meeting Abstract April 2011

Efficacy of Dexamethasone Intravitreal Implant for Best Corrected Visual Acuity in Patients With Retinal Vein Occlusion After 7 Days

Baruch D. Kuppermann; Julia A. Haller; Francesco Bandello; Rubens Belfort, Jr.; Anat Loewenstein; Mark Gillies,; Jeffrey S. Heier; Jenny Jiao; Xiao-Yan Li; Scott M. Whitcup

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3966. doi:

ARVO Annual Meeting Abstract April 2011

Efficacy and Safety of Combination Therapy with Dexamethasone Intravitreal Implant (DEX Implant) Plus Laser Photocoagulation Versus Monotherapy With Laser for Treatment of Diffuse Diabetic Macular Edema (DDME)

David Callanan; Sunil Gupta; Thomas A. Ciulla; David S. Boyer; Ching-Chi Liu; Jean Lou; Xiao-Yan Li; Scott M. Whitcup

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3968. doi:

ARVO Annual Meeting Abstract April 2011

Normative Comparison of Patient-Reported Outcomes in Patients With Noninfectious Intermediate or Posterior Uveitis

Rupali K. Naik; Careen Y. Lowder; Sue Lightman; Anne M. Rentz; Jonathan Kowalski; C. Stephen Foster; Rubens Belfort, Jr.; Dennis Revicki; Scott M. Whitcup

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):2729. doi:

ARVO Annual Meeting Abstract April 2011

Dexamethasone Intravitreal Implant (DEX Implant) Alone And As An Adjunct To Ranibizumab For The Treatment Of Choroidal Neovascularization (CNV) Secondary To Age-related Macular Degeneration (AMD)

Michael Singer; Sunil S. Patel; Harvey S. Uy; Ching-Chi Liu; Xiao-Yan Li; Scott M. Whitcup

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3536. doi:

ARVO Annual Meeting Abstract April 2011

Retinal Vascular Changes Following Treatment With Dexamethasone Intravitreal Implant (DEX Implant) in Patients With Macular Edema (ME) Secondary to Branch or Central Retinal Vein Occlusion (RVO)

Xiao-Yan Li; Srinivas Sadda; Ronald P. Danis; Jenny Jiao; Scott M. Whitcup

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1259. doi:

ARVO Annual Meeting Abstract April 2011

Central Retinal Thickness Following Dexamethasone Intravitreal Implant Treatment in Patients With Macular Edema Due to Branch or Central Retinal Vein Occlusion

Ronald P. Danis; Srinivas Sadda; Jenny Jiao; Xiao-Yan Li; Scott M. Whitcup

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):1260. doi:

Retina January 2011

Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant

PDF

Joan-En Chang-Lin; Mayssa Attar; Andrew A. Acheampong; Michael R. Robinson; Scott M. Whitcup; Baruch D. Kuppermann; Devin Welty
TAGS: dexamethasone, implants, intravitreal implants, pharmacodynamics, pharmacokinetics, retina, vitreous body, eye, plasma, mass or substance concentration per volume
Invest. Ophthalmol. Vis. Sci.. 2011; 52(1):80-86. doi: https://doi.org/10.1167/iovs.10-5285

Research Opportunities November 2010

Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Applications

PDF

Henry F. Edelhauser; Cheryl L. Rowe-Rendleman; Michael R. Robinson; Daniel G. Dawson; Gerald J. Chader; Hans E. Grossniklaus; Kay D. Rittenhouse; Clive G. Wilson; David A. Weber; Baruch D. Kuppermann; Karl G. Csaky; Timothy W. Olsen; Uday B. Kompella; V. Michael Holers; Gregory S. Hageman; Brian C. Gilger; Peter A. Campochiaro; Scott M. Whitcup; Wai T. Wong
TAGS: drug clearance, drug delivery systems, eye, ophthalmic agents, retinal diseases, retina, body tissue, vitreous body, permeability, basic science research
Invest. Ophthalmol. Vis. Sci.. 2010; 51(11):5403-5420. doi: https://doi.org/10.1167/iovs.10-5392

Includes: Supplemental Content

Cornea August 2002

Conjunctival T-Cell Subpopulations in Sjögren’s and Non-Sjögren’s Patients with Dry Eye

PDF

Michael E. Stern; Jianping Gao; Tammy A. Schwalb; Mylinh Ngo; David D. Tieu; Chi-Chao Chan; Brenda L. Reis; Scott M. Whitcup; Darby Thompson; Janine A. Smith
TAGS: biopsy, conjunctiva, dry eye syndromes, sjogren's syndrome, t-lymphocytes, immunohistochemistry, antibodies, inflammation, hla-dr antigens
Invest. Ophthalmol. Vis. Sci.. 2002; 43(8):2609-2614. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

A Phase 2 Multicenter, Randomized, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of CBT-001 for Pterygia

Pharmacology of Corticosteroids for Diabetic Macular Edema

Persistent diabetic macular edema after 6 months of anti-VEGF therapy is associated with diminished long-term improvement in vision: a post-hoc analysis of Protocol I

Consistency of visual acuity response to anti-VEGF therapy in diabetic macular edema patients: An analysis of DRCRnet Protocol I data

Long-term Efficacy and Safety of Dexamethasone Intravitreal Implant in Phakic and Pseudophakic Eyes with Diabetic Macular Edema

Anatomic Outcomes with Dexamethasone Intravitreal Implant in Diabetic Macular Edema: a Pooled Analysis of Two Randomized Phase 3 Trials

Three-year, Randomized, Sham-controlled, Phase III Study of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema

Vision-Related Functioning Outcomes of Dexamethasone Intravitreal Implant in Noninfectious Intermediate or Posterior Uveitis

Pharmacokinetics of a Sustained-Release Dexamethasone Intravitreal Implant in Vitrectomized and Nonvitrectomized Eyes

Treatment of Experimental Anterior and Intermediate Uveitis by a Dexamethasone Intravitreal Implant

Association Between Duration of Macular Edema and Clinical Outcomes in Patients with Retinal Vein Occlusion Following Treatment With Dexamethasone Intravitreal Implant

Efficacy of Dexamethasone Intravitreal Implant for Best Corrected Visual Acuity in Patients With Retinal Vein Occlusion After 7 Days

Efficacy and Safety of Combination Therapy with Dexamethasone Intravitreal Implant (DEX Implant) Plus Laser Photocoagulation Versus Monotherapy With Laser for Treatment of Diffuse Diabetic Macular Edema (DDME)

Normative Comparison of Patient-Reported Outcomes in Patients With Noninfectious Intermediate or Posterior Uveitis

Dexamethasone Intravitreal Implant (DEX Implant) Alone And As An Adjunct To Ranibizumab For The Treatment Of Choroidal Neovascularization (CNV) Secondary To Age-related Macular Degeneration (AMD)

Retinal Vascular Changes Following Treatment With Dexamethasone Intravitreal Implant (DEX Implant) in Patients With Macular Edema (ME) Secondary to Branch or Central Retinal Vein Occlusion (RVO)

Central Retinal Thickness Following Dexamethasone Intravitreal Implant Treatment in Patients With Macular Edema Due to Branch or Central Retinal Vein Occlusion

Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant

Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Applications

Conjunctival T-Cell Subpopulations in Sjögren’s and Non-Sjögren’s Patients with Dry Eye

To View More...

You must be signed into an individual account to use this feature.